Skip to main content
Premium Trial:

Request an Annual Quote

NCI Launches $14M Breast and Prostate Cancer Initiative; Illumina to Do Genotyping

NEW YORK, Feb. 13 (GenomeWeb News) - The National Cancer Institute launched an initiative to identify genetic susceptibilities to prostate and breast cancer, the National Institutes of Health announced today.

 

Illumina has been tapped to do rapid genotyping for the project, NIH said, beginning with 2,500 male samples for the prostate cancer portion of the research.

 

The Cancer Genetic Markers of Susceptibility project is a three-year initiative with $14 million in funding, according to a statement.

 

The initiative will analyze as many as 500,000 SNPs in each cancer case or control. NCI's Division of Cancer Epidemiology, Core Genotyping Facility, and Office of Cancer Genomics will coordinate the project.

 

CGEMS data will be available via NCI's caBIG project.

The Scan

Comfort of Home

The Guardian reports that AstraZeneca is to run more clinical trials from people's homes with the aim of increasing participant diversity.

Keep Under Control

Genetic technologies are among the tools suggested to manage invasive species and feral animals in Australia, Newsweek says.

Just Make It

The New York Times writes that there is increased interest in applying gene synthesis to even more applications.

Nucleic Acids Research Papers on OncoDB, mBodyMap, Genomicus

In Nucleic Acids Research this week: database to analyze large cancer datasets, human body microbe database, and more.